Boehringer Ingelheim AB Company Profile

06:45 EST 10th December 2018 | BioPortfolio



Box 47608
117 94


Phone: 08-721 21 22

News Articles [287 Associated News Articles listed on BioPortfolio]


Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires. BOEHRINGER INGELHEIM - Der Pharmakonzern Boehringer Ingelheim strukturiert seine Wirkstoffproduktion um. ...

Boehringer Ingelheim Partners with Epizyme

Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small molecule inhibitors direct...

Deals this week: Boehringer Ingelheim, UCB, Janssen Pharmaceutical

Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project. Both the companies have...Read More... The post Deals this week: Boehringer Ingelheim, UCB,...

Boehringer Ingelheim inaugurates new centre for agile working methods

Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. The sustainably built and innova...

Boehringer Ingelheim acquires MabVax’s programme for solid tumours

Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target...Read More... The post Boehringer Ingel...

Is Boehringer Ingelheim moving away from traditional medicines in favour of biopharmaceuticals?

Allan Hillgrove, Corporate Board Division, Pharma Marketing and Sales discusses the ongoing transformation of Boehringer Ingelheim’s portfolio.

Boehringer Ingelheim investiert in Forschungszentrum in Biberach

Das Pharmaunternehmen Boehringer Ingelheim baut für 230 Millionen Euro ein neues Entwicklungszentrum für biotechnisch produzierte Wirkstoffe. Dies sei ein weiterer wichtiger Baustein der langfrist.....

Boehringer investiert 128 Millionen Euro am Stammsitz Ingelheim

Der Pharmakonzern Boehringer Ingelheim hat eine weitere millionenschwere Investition am Stammsitz in Ingelheim angekündigt. Für rund 128 Millionen Euro solle bis Ende 2021 ein "Neues Technikum" en.....

Drugs and Medications [59 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Boehringer-Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma.

Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.

Oral inhalation is the recommended delivery method of medications for the treatment of patients with chronic obstructive pulmonary disease (COPD). However, patients may struggle when using the various...

Establishment of a CFD-based k a model in microtiter plates to support CHO cell culture scale-up during clone selection.

Microtiter plates are a common tool for clone selection in biopharmaceutical development. A way of visualizing and evaluating these systems and key processes parameters is the application of Computati...

Clinical Trials [22 Associated Clinical Trials listed on BioPortfolio]

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Companies [41 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the U.S. headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

More Information about "Boehringer Ingelheim AB" on BioPortfolio

We have published hundreds of Boehringer Ingelheim AB news stories on BioPortfolio along with dozens of Boehringer Ingelheim AB Clinical Trials and PubMed Articles about Boehringer Ingelheim AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boehringer Ingelheim AB Companies in our database. You can also find out about relevant Boehringer Ingelheim AB Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record